Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

What Was Tested

This randomized controlled trial paper looks at Leuprolide and Degarelix.

The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.

Who Took Part

PubMed indexes the participants as older adults, men only.

In this international, multicenter, prospective, randomized, open-label trial, men with prostate cancer and concomitant atherosclerotic cardiovascular disease were randomly assigned 1:1 to receive the GnRH antagonist degarelix or the GnRH agonist leuprolide for 12 months.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Leuprolide and who got the comparison, which limits bias.

Everyone knew when Leuprolide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

The timeline in the abstract includes 12 months.

What Was Measured

Topics PubMed links to this paper include Leuprolide, Oligopeptides and Prostatic Neoplasms.

Author keywords: agonists, atherosclerosis, cardiotoxicity, drug therapy and gonadotropin-releasing hormone.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Leuprolide and Degarelix over 12 months.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Circulation), a journal based in United States.

More context: the Leuprolide compound page and the Degarelix compound page, all human trials.